Carbetocin vs Misoprostol for Postpartum Hemorrhage Prevention

What Was Tested

The trial (not phased) is built around Carbetocin.

Postpartum hemorrhage (PPH) is a leading cause of maternal morbidity and mortality worldwide, particularly among women with known risk factors.

Carbetocin, a long-acting oxytocin analogue, and misoprostol are both used for this purpose, but comparative data in high-risk vaginal deliveries remain limited.

It had two arms (groups): Carbetocin arm (experimental) and Misoprostol arm (active comparator).

The registry classes the interventions as drug.

More on the Plan

Postpartum hemorrhage (PPH), most commonly caused by uterine atony, remains a major contributor to maternal morbidity and mortality.

This prospective, randomized, single-center study will enroll women at term with singleton pregnancies and predefined risk factors for postpartum hemorrhage.

The primary outcome is the occurrence of postpartum hemorrhage.

Who Took Part

146 planned participants were the target.

It was open to women only aged from 18 years with no upper age limit.

Healthy volunteers were not accepted; participants needed the condition being studied.

Examples of who could join: Women aged 18 years or older. Gestational age 37-42 weeks. Presence of one or more risk factors for postpartum hemorrhage, including:. Grand multiparity (≥5 previous deliveries). History of postpartum hemorrhage.

The full record lists 15 inclusion and 8 exclusion criteria; among the exclusions: multiple gestation; known major fetal anomalies; intrauterine fetal demise (iufd).

How the Study Was Run

It was run as a randomized, parallel-group and open-label study.

Because people in this Carbetocin study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

The Carbetocin group and the comparison group ran side by side rather than switching.

Nothing was hidden in this open-label Carbetocin study: the participants and staff both knew the treatment.

It started in 2026-01-31 with completion listed for 2028-01-01.

Its stated primary purpose is prevention.

What Was Measured

Primary outcome: Postpartum hemorrhage (PPH) (time frame: Within 24 hours after delivery). Need for additional uterotonic treatment or surgical intervention (time frame: Within 24 hours of delivery).

It also tracked 3 secondary outcomes, for example Change in hemoglobin level, Blood transfusion requirement and Maternal adverse effects related to study medications.

What This Means in Plain Language

Put simply, this is a not phased, randomized trial of Carbetocin in 146 people.

Its status is not yet recruiting; no results are posted to the registry yet, so nothing here describes outcomes.

More context: the Carbetocin compound page, all human trials.